Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

China rejects WHO plan for study of COVID-19 origin

Published 07/22/2021, 02:01 AM
Updated 07/22/2021, 03:31 PM
© Reuters. FILE PHOTO: A logo is pictured outside a building of the World Health Organization (WHO) during an executive board meeting on update on the coronavirus disease (COVID-19) outbreak, in Geneva, Switzerland, April 6, 2021. REUTERS/Denis Balibouse/File Photo

By Gabriel Crossley

BEIJING (Reuters) -China rejected on Thursday a World Health Organization (WHO) plan for a second phase of an investigation into the origin of the coronavirus, which includes the hypothesis it could have escaped from a Chinese laboratory, a top health official said.

The WHO this month proposed a second phase of studies into the origins of the coronavirus in China, including audits of laboratories and markets in the city of Wuhan, calling for transparency from authorities.

"We will not accept such an origins-tracing plan as it, in some aspects, disregards common sense and defies science," Zeng Yixin, vice minister of the National Health Commission (NHC), told reporters.

Zeng said he was taken aback when he first read the WHO plan because it lists the hypothesis that a Chinese violation of laboratory protocols had caused the virus to leak during research.

The head of the WHO said earlier in July that investigations into the origins of the COVID-19 pandemic in China were being hampered by the lack of raw data on the first days of spread there.

Zeng reiterated China's position that some data could not be completely shared due to privacy concerns.

"We hope the WHO would seriously review the considerations and suggestions made by Chinese experts and truly treat the origin tracing of the COVID-19 virus as a scientific matter, and get rid of political interference," Zeng said.

China opposed politicising the study, he said.

The origin of the virus remains contested among experts.

The first known cases emerged in the central Chinese city of Wuhan in December 2019. The virus was believed to have jumped to humans from animals being sold for food at a city market.

In May, U.S. President Joe Biden ordered aides to find answers to questions over the origin, saying that U.S. intelligence agencies were pursuing rival theories potentially including the possibility of a laboratory accident in China.

White House press secretary Jen Psaki said on Thursday that the Biden administration is "deeply disappointed" in China's decision and told reporters that "their position is irresponsible and, frankly, dangerous."

Zeng, along with other officials and Chinese experts at the news conference, urged the WHO to expand origin-tracing efforts beyond China to other countries.

"We believe a lab leak is extremely unlikely and it is not necessary to invest more energy and efforts in this regard," said Liang Wannian, the Chinese team leader on the WHO joint expert team. More animal studies should be conducted, in particular in countries with bat populations, he said.

However, Liang said the lab leak hypothesis could not be entirely discounted but suggested that if evidence warranted, other countries could look into the possibility it leaked from their labs.

© Reuters. FILE PHOTO: A logo is pictured outside a building of the World Health Organization (WHO) during an executive board meeting on update on the coronavirus disease (COVID-19) outbreak, in Geneva, Switzerland, April 6, 2021. REUTERS/Denis Balibouse/File Photo

One key part of the lab leak theory has centred on the Wuhan Institute of Virology's (WIV) decision to take offline its gene sequence and sample databases in 2019.

When asked about this decision, Yuan Zhiming, professor at WIV and the director of its National Biosafety Laboratory (NYSE:LH), told reporters that at present the databases were only shared internally due to cyber attack concerns.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.